monoclonal antibody

Luzhu's major products are currently in the research and development stage and it does not have any approved products for sale, and has suffered a loss of over 1.5 billion yuan in the past three years.

FAST NEWS: Luzhu Biotech repurchases shares

The Latest: Beijing Luzhu Biotechnology Co. Ltd. (2480.HK) announced Monday that it repurchased a combined 1.43 million of the company’s shares on July 12 and 15, after its board authorized…
2480.HK

Recent Articles

RELATED ARTICLES

  1. After a Beijing IPO last year, the loss-making biotech has also filed for a Hong Kong listing to better compete in the crowded market for HPV vaccines.
    Health Guard plans dual listing to fund HPV vaccine fight
  2. China’s mRNA pioneer Stemirna faces post-Covid reinvention test
  3. Forget about growth. Qifu shows it’s all about giving back to shareholders
    QFIN.US
  4. Yum China revs up restaurant expansion, share repurchases
    9987.HK YUMC.US
  5. FAST NEWS: C-Mer Eye repurchases HK$4.9 million worth of shares
    3309.HK
  6. Makeover complete? Yatsen says the worst may be behind it
    YSG.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva